The Union Health Ministry has suggested a crucial regulatory reform that could speed up and potentially cut the cost of life-saving plasma-derived medicines to hospitals while maintaining tight safety standards. The Ministry of Health and Family Welfare has released a draft notification seeking public feedback on a proposal to change the testing procedures for blood products under the Drugs Procedures of 1945. 

The draft amendment, which was published as Gazette notification GSR 164(E) on March 9, 2026, suggests doing rid of what experts describe duplicate layer of viral testing for commodities made from blood. Officials said the change is meant to bring India's rules in line with internationally acknowledged pharmacopoeial standards while making it easier for companies to follow the rules. 

Pharmaceutical companies in India that make drugs from human plasma must test for viral infections, such as hepatitis B, hepatitis C, and HIV, at two different times. First, the pooled plasma that was utilised to make the medicines is looked at. After the drug is made, the same testing for viruses are done on the finished product.

According to health officials, the initial phase of testing already meets tough international requirements, ensuring that only virus-free plasma pools are utilised in manufacturing. "The proposal seeks to remove additional testing requirements that are not warranted under globally accepted best practices," the ministry stated, urging stakeholders to provide feedback. 

Plasma is the pale yellow liquid element of blood that contains proteins required to cure a variety of significant medical diseases. Plasma-derived medicines are commonly used to treat immunological disorders, bleeding problems like haemophilia, and certain neurological ailments. 

Scientists mix plasma from numerous donors into what they call a "pooled plasma batch" before they can make medications like these. It is important to carefully check this pooled plasma for signs of viruses such hepatitis B surface antigen, hepatitis C virus RNA, and antibodies to HIV. It will only be cleared for further processing if the whole plasma pool is negative for these markers. 

The next step in the production process is called fractionation. This is when different therapeutic proteins are carefully separated from plasma to manufacture medicines like immunoglobulins, clotting factors, and albumin. 

A lot of the time, experts use a simple analogy to communicate the topic. If all the materials used to produce a cake have already been tested and found to be safe, testing the finished cake for the same contamination could not help at all. Similarly, once a plasma pool has been thoroughly screened and certified, doing the same viral test on the final product may not yield new results. 

International pharmacopoeias, such as the Indian Pharmacopoeia, British Pharmacopoeia, United States Pharmacopoeia, and European Pharmacopoeia, have previously used this technique. They require rigorous testing of pooled plasma before it can be utilised for fractionation. 

However, India's existing regulatory structure requires an additional layer of testing for completed products. According to industry experts, repeated testing can increase manufacturing time, costs, and logistical complexity while not boosting safety. 

Health officials underline that the planned modification will not reduce protections against illnesses like HIV or hepatitis. The initial examination of pooled plasma will remain necessary and thorough. The change simply seeks to eliminate repetition, which global regulatory systems no longer deem necessary. 

Plasma-derived drugs are generally pricey, according to public health experts, due to the complex and heavily regulated manufacturing process. Any effort that lowers needless delays or costs may eventually enhance availability for patients who rely on these therapies. 

The government has now launched the plan for public consultation, allowing healthcare professionals, industry stakeholders, and residents to provide feedback before the modification is finalised. Officials say the move is part of a larger attempt to update India's drug regulations and align them with global scientific standards while prioritising patient safety. 

For many patients who rely on plasma-based treatments, the reform may be a tiny but significant step toward speedier access to critical medicines while maintaining the stringent safety checks that protect public health.